GSK3A and acute myeloid leukemia: Lower levels of p-GSK-3α/β in AML cells, measured by reverse phase protein analysis, correlated with longer remission duration and overall survival in patients with intermediate-risk, but not unfavorable-risk, karyotypes (51).